SABS – sab biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Form 8-K SAB Biotherapeutics, For: Jan 12
Form EFFECT SAB Biotherapeutics,
Form 4 SAB Biotherapeutics, For: Jan 05 Filed by: Jain Rita
Form 4 SAB Biotherapeutics, For: Jan 05 Filed by: ZACCARDELLI DAVID
Form 3 SAB Biotherapeutics, For: Jan 05 Filed by: Jain Rita
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.